81. Indiacancer.org - Myelodysplastic Syndromes What are myelodysplastic syndromes? Usually a disease of the older people, myelodysplastic syndromes may also be seen in younger people. http://www.indiacancer.org/coca/m/ms.html

Myelodysplastic Syndromes What is the Bone Marrow? What are Myelodysplastic Syndromes? How do Myelodysplastic Syndromes present? How are Myelodysplastic Syndromes detected? ... What is the importance of follow up? What is the Bone Marrow? The bone marrow is a spongy tissue, which is found mainly in the large bones in the body. The bone marrow is responsible for production of most of the blood's formed elements, which include the red blood cells (carriers of oxygen to all tissues of the body), white blood cells (fighters of infection), and platelets (clotters of blood). Usually, the bone marrow makes cells called blasts that ultimately mature into various types of blood cells, and each of these types of blood cells have specific jobs to do in the body. What are Myelodysplastic Syndromes? These are a rare group of diseases also known as a preleukaemia or smouldering leukaemia , and they are basically diseases of the bone marrow. In these diseases, the bone marrow fails to function normally and an inadequate number of blood cells which are normal, are produced.

82. Scientific Programme Session. myelodysplastic syndromes. Date Saturday, 8 June 2002. Time 11301245. Room Tiziano. 1130-1145, 0602. DECREASED PHOSPHORYLATION http://www.parthen-impact.com/cgi-bin/pco/6_EHA7/public/index.cgi?unit=pub_sessi

83. Scientific Programme Session. Poster session myelodysplastic syndromes Clinical. Date Saturday, 8 June 2002. Time 1715-1845. Room 1715-1845, 1061. http://www.parthen-impact.com/cgi-bin/pco/6_EHA7/public/index.cgi?unit=pub_sessi

84. ASH ONLINE myelodysplastic syndromes. By Sonali M. Smith, MD, and Richard A. Larson, MD The myelodysplastic syndromes (MDS) are a heterogeneous http://www.hematology.org/meeting/2002/newsdaily/myelodysplasticsyndromes.cfm

Search Site Map Contact Us Home ... Quality Care Myelodysplastic Syndromes By Sonali M. Smith, M.D., and Richard A. Larson, M.D. The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by dyspoiesis and propensity for leukemic evolution. New insights into underlying immunologic and molecular defects potentially leading to more targeted treatment strategies are the subject of this year’s myelodysplastic syndromes education session (Saturday, 8:00 a.m., and 2:00 p.m.) Dr. Peter L. Greenberg provides an overview of the clinical approach and treatment options with emphasis on risk stratification using the International Prognostic Scoring System (IPSS). However, newer means of risk stratification in this heterogenous disease challenge the applicability of the IPSS in current clinical decision-making. For example, Hofmann and colleagues (abstract 621) will discuss the use of gene expression profiling to identify genes that discriminate low-risk from high-risk patients during the myelodysplastic syndromes Preclinical Investigations simultaneous session (Monday, 3:15 p.m.-5:15 p.m.), while Benesch and colleagues (abstract 358) will discuss the use of pre-transplantation bone marrow flow cytometric analysis as a prognostic tool for post-transplant clinical outcome at the

85. Cancer Spectrum PDQ - Summary . What are myelodysplastic syndromes? What are myelodysplastic syndromes?...... (Health Professional Version). myelodysplastic syndromes. http://jncicancerspectrum.oupjournals.org/cgi/pdq/jncipdq;CDR0000062723

Content Sources... JNCI: Current Issue Past Issues Monographs Collections Online Perspectives Journals Cancer News Databases: PDQ PDR Cancer Drugs Cochrane Reviews IARC Monographs Statistics: SEER IARC Incidence WHO Mortality Calendar Useful Links Cancer Dictionary Sign In to JNCI Cancer Spectrum Quick Search Select area All JNCI Journals Cancer Statistics PDQ Cochrane Reviews IARC Monographs PDR Calendar Useful Links Other Search Options Current Issue Past Issues Monographs ... Submission Information Free Sample Issue Table of Contents Alerting Editorial Board About JNCI Search JNCI Other Journals ... Search Cancer Statistics Subscriptions Advertising About JNCI Cancer Spectrum Contact Us Go To: Home Physician Data Query Treatment (Health Professional Version) Myelodysplastic Syndromes Description What are myelodysplastic syndromes? Stage Explanation Stages of myelodysplastic syndromes ... About PDQ Description What are myelodysplastic syndromes? What are myelodysplastic syndromes? Myelodysplastic syndromes, also called pre-leukemia or “smoldering” leukemia, are diseases in which the bone marrow does not function normally and not enough normal blood cells are made. The bone marrow is the spongy tissue inside the large bones in the body. The bone marrow makes red blood cells (which carry oxygen and other materials to all tissues of the body), white blood cells (which fight infection), and platelets (which make the blood clot). Normally, bone marrow cells called blasts develop (mature) into several different types of blood cells that have specific jobs in the body.

86. Cancer Symptoms Treatments - Dana-Farber Cancer Institute Back to List of Diagnoses. myelodysplastic syndromes ID Number(s), Trial Title, Previous Next. • EORTC58921, Phase III Randomized http://www.dana-farber.org/can/clinical/triallist.asp?type=protocol&dis=02495&au

87. Disease Category Listing (516): Myelodysplastic Syndromes (MDS) CenterWatch Listing of Clinical Research Trials for myelodysplastic syndromes (MDS). Clinical Trials myelodysplastic syndromes (MDS). North Carolina. http://www.centerwatch.com/patient/studies/cat516.html

Clinical Trials: Myelodysplastic Syndromes (MDS) North Carolina Winston-Salem; Wake Forest University School of Medicine Orthomolecular vitamin D in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial Back to Clinical Trials by Medical Areas Research centers specializing in this illness area Additional resources ... in this illness area This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Trial listing updated: May 17, 2004 at 2:49:22 PM Patient Resources: [ Trial Listing Notification Services Drug Directories About Clinical Research ... Patient Bookstore Professional Resources: [ Research Center Profiles Industry Provider Profiles Industry News Professional Resources ... Professional Bookstore General: [ Search Site Map Your Privacy CW World ... Home This site was developed in association with Illumina Interactive of Boston, MA

88. Sloan-Kettering - Myelodysplastic Syndrome: Our Approach & Expertise confused. field. Memorial SloanKettering has been designated a Center of Excellence by the myelodysplastic syndromes Foundation. http://www.mskcc.org/mskcc/html/8190.cfm

var tab = tabs[tabs.length] = []; tab.id = 12; var TAB_WWWROOT = "/mskcc/"; var tabDarkColor = "#336699"; var tabMediumColor = "#99BBCC"; createHeaderImageCache(44,512,5626,1072,5664,638,8228); formatTabs(tabs); Cancer Information Types of Cancer Myelodysplastic Syndrome Select a Myelodysplastic Syndrome Topic - Overview - Risk Factors - Symptoms - Diagnosis - Treatment - After Treatment Proper care of patients with myelodysplastic syndrome (MDS) is critically dependent on a correct diagnosis. Doctors at Memorial Sloan-Kettering are expert at distinguishing MDS from the many other conditions with which it is often confused. Physicians here employ an array of sophisticated technologies such as cytogenetic, molecular, and immunohistochemistry studies to characterize blood and bone marrow cells precisely and identify the most appropriate course of treatment for individual patients. Memorial Sloan-Kettering's Hematology Disease Management Team provides comprehensive, multidisciplinary care to patients with MDS. The team includes hematologists, pathologists, cytogeneticists, blood bank physicians, bone marrow transplant physicians, and other specialists who treat more than 100 new MDS patients each year and who are internationally recognized for their expertise in the field. Memorial Sloan-Kettering has been designated a Center of Excellence by the Myelodysplastic Syndromes Foundation. Overview Risk Factors Symptoms Diagnosis ... After Treatment Last Updated: Feb. 25, 2002

89. BloodMed - Subject Section Go back. Prognosis and Treatment of the myelodysplastic syndromes. 2. HellstromLindberg E. Treatment of adult myelodysplastic syndromes. Int. J. Hematol. http://www.bloodmed.com/200000/reviewarticle1.asp?id=125

90. Images.MD: View Collection Leukemia. section myelodysplastic syndromes. The results of your search are displayed below. Differential diagnosis of myelodysplastic syndromes. http://images.md/users/explore_chapter.asp?ID=ACNCR01-06-40&colID=ACNCR01-06&col

91. Myelodysplastic Syndrome And Its Treatment FAB Cooperative Group. Proposals for the classification of the myelodysplastic syndromes. Mufti G. Chromosomal deletions in the myelodysplastic syndromes. http://www.centerspan.org/pubs/news/0597c.htm

Spring 1997 Volume 4, Number 1 SUBTITLE Myelodysplastic Syndrome and Its Treatment The term myelodysplastic syndrome (MDS) is used to describe a condition characterized by refractory cytopenias in patients whose bone marrows reveal dysplastic changes in at least two of the three hematopoietic cell lines. MDS often undergoes transformation into acute myeloid leukemia (AML), and the leukemias in these patients are generally less responsive to standard induction chemotherapy than those which arise de novo. Therefore, although the morphology of AML is similar regardless of whether the disease develops de novo or after transformation from MDS, the biology of the disease is not. Variations in marrow morphology and differing potentials for survival and transformation to AML among cases of MDS have led to the establishment of a morphologic classification scheme with five subgroups (see table on this page): refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMML). RA and RARS patients have fewer than 5% blasts in their bone marrow; RAEB patients have 5-20% blasts, and RAEB-T patients 20-30% blasts. Patients with AML have more than 30% blasts in their bone marrow. MDS can develop de novo (primary MDS) or can arise as a result of prior chemotherapy or chemoradiotherapy for other malignancies or as a result of exposure to a variety of marrow toxins (secondary MDS). Approximately 40-60% of patients with primary MDS have cytogenetic abnormalities at diagnosis, whereas more than 80% of patients with secondary MDS have abnormal karyotypes.

92. NEJM -- Apoptosis In Myelodysplastic Syndromes Images in Clinical Medicine from The New England Journal of Medicine Apoptosis in myelodysplastic syndromes. Next Next. Apoptosis in myelodysplastic syndromes. http://content.nejm.org/cgi/content/short/340/21/1639

HOME SEARCH CURRENT ISSUE PAST ISSUES ... HELP Please sign in for full text and personal services Previous Volume 340:1639 May 27, 1999 Number 21 Next Apoptosis in Myelodysplastic Syndromes Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings. Full Text PDF Add to Personal Archive Add to Citation Manager ... PubMed Citation View larger version [in this window] [in a new window] A 45-year-old man presented with pancytopenia due to myelodysplastic syndrome. The bone marrow showed marked trilineage dysplasia. Electron microscopy revealed that the majority of hematopoietic cells in the marrow had ultrastructural features of various stages of apoptosis ranging from margination and condensation of nuclear chromatin (arrowhead) to full nuclear pyknosis and vacuolization of the cytoplasm, with polarization of the organelles (arrow, x These findings suggest that in myelodysplasia, the proliferation of hematopoietic cells is outstripped by a simultaneous increase in the rate of apoptosis in the bone marrow. Giorgio Lambertenghi Deliliers, M.D.

93. THE MERCK MANUAL, Sec. 11, Ch. 138, Leukemias myelodysplastic syndrome (MDS) is a group of syndromes (preleukemia, refractory anemias, Phnegative chronic myelocytic leukemia, chronic myelomonocytic http://www.merck.com/mrkshared/mmanual/section11/chapter138/138d.jsp

94. Society : - Leukemia print page. email page. myelodysplastic Syndrome Begin Reading http://www.leukemia-lymphoma.org/all_mat_toc.adp?item_id=54083

95. Myelodysplastic Syndrome (MDS) Clinical Trials myelodysplastic Syndrome (MDS) Clinical Trials at The Norris Cotton Cancer Center. Email Address myelodysplastic Syndrome (MDS) Clinical Trials. http://www.cancer.dartmouth.edu/clinicaltrials/mds.shtml

In Affiliation with: Dartmouth Medical School Dartmouth-Hitchcock Medical Center The National Cancer Institute Welcome to Norris Cotton Cancer Center Contact About Directions Media You are: Home Clinical Trials Quick Links Clinical Services Patient Support Services Clinical Trials Research ... Giving and Volunteering Mailing List Enter your email address to receive periodic updates from the Cancer Center. Email Address Myelodysplastic Syndrome (MDS) Clinical Trials For further information on clinical trial eligibility or informed consent call: Norris Cotton Cancer Center Clinical Research Office at 603-650-7609 RTOG Clinical Trials at 603-650-6425. Disease Site Number Study Title Myelodysplastic Syndromes Compassionate Use of Subcutaneous 5-Azacytadine in Myelodysplastic Syndromes Clinical Trials Clinical Trial Index View all Trials Clinical Research Office Contact Numbers for Clinical Trials ... NCCC Membership in National Cooperative Clinical Trials Organizations Learn More About Clinical Trials Understanding Clinical Trials ," from the National Cancer Institute Institutional Data and Safety Monitoring Plan Related Links Phase I Trials Biostatistics Shared Resource ... Mary Hitchcock Memorial Hospital Cancer Registry In Affiliation with: Dartmouth Medical School Dartmouth-Hitchcock Medical Center The National Cancer Institute Norris Cotton Cancer Center One Medical Center Drive Lebanon, New Hampshire (NH) 03756

96. Sloan-Kettering - Myelodysplastic Syndrome: Treatment Current treatment strategies are designed to slow the progression of myelodysplastic syndrome and to alleviate symptoms. http://www.mskcc.org/mskcc/html/8192.cfm

var tab = tabs[tabs.length] = []; tab.id = 12; var TAB_WWWROOT = "/mskcc/"; var tabDarkColor = "#336699"; var tabMediumColor = "#99BBCC"; createHeaderImageCache(44,512,5626,1072,5664,638,8228); formatTabs(tabs); Cancer Information Types of Cancer Myelodysplastic Syndrome Treatment Treatment Select a Myelodysplastic Syndrome Topic - Overview - Risk Factors - Symptoms - Diagnosis - Treatment - After Treatment Physicians devise a course of treatment for each myelodysplastic syndrome (MDS) patient that takes a number of factors into consideration: the severity of the disease; whether the patient has already been treated already, with what, and how successfully; and the patient's age and overall health. For most MDS patients, no currently available treatment is considered a cure. Current treatment strategies are designed to slow the progression of disease and to alleviate symptoms. Younger MDS patients those 50 years and younger may be eligible for a bone marrow transplant, which has been found to be curative in about 25 percent of cases. Studies show that patients with the RA (refractory anemia) and RARS (refractory anemia with ringed sideroblasts) subtypes of MDS are more likely to do better following a bone marrow transplant than those with subtypes RAEB (refractory anemia with excess blasts) and RAEB-t (refractory anemia with excess blasts in transformation). For patients who are not eligible for bone marrow transplant, treatment options include supportive care, an approach that includes blood and platelet transfusions, antibiotics to treat infection, and erythropoietin, a hormone that stimulates the body to produce red blood cells and G-CSF (granulocyte colony stimulating factor), a growth factor that stimulates production of white blood cells.

97. US Rep. J. Moakley Has Rare Disorder Feature article on Rep. J. Joseph Moakley and myelodysplastic syndrome (MDS), dated 2/13/01. NCI/PDQ Patient Statement myelodysplastic syndrome. http://rarediseases.about.com/library/weekly/aa021301a.htm

zJs=10 zJs=11 zJs=12 zJs=13 zc(5,'jsc',zJs,9999999,'') About Rare / Orphan Diseases Home Essentials ... Rare cancers zau(256,152,145,'gob','http://z.about.com/5/ad/go.htm?gs='+gs,''); Is it a Rare Disease? Rare Diseases A - B Rare Diseases C - D Rare Diseases E - H ... Help zau(256,138,125,'el','http://z.about.com/0/ip/417/0.htm','');w(xb+xb); Stay Current Subscribe to the About Rare / Orphan Diseases newsletter. zau(256,152,100,'hs','http://z.about.com/5/ad/hs.htm?zIhsid=00',''); Search Rare / Orphan Diseases US Rep. J. Moakley Has Rare Disorder Has serious disease Related Resources Internet links on myelodysplastic syndrome Internet links on leukemia Elsewhere on the Web CNN.com: Bush honors Congressman Moakley U.S. Congress Biography: J. Joseph Moakley Mary Kugler, MSN, RN,C Guide to Rare/Orphan Diseases February 13, 2001 Updated May 28, 2001 It started as being short of breath when he walked up stairs. Representative J. Joseph Moakley (D-Mass.) thought it was caused by being "about 65 pounds overweight." His doctor had trouble diagnosing what was happening, until low blood cell and platelet counts pointed in the direction of a blood disorder. A bone marrow biopsy at Bethesda Naval Hospital confirmed the bad news. On Monday, February 12, 2001, Moakley announced at a press conference in Boston that he has been diagnosed with myelodysplastic syndrome (MDS), which is evolving into erythroleukemia (blood cancer).

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 5     81-97 of 97    Back | 1  | 2  | 3  | 4  | 5